Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TBIO-6517 + pembrolizumab
- Development stage
- Unknown
- Lead developer
- Turnstone Biologics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Oncolytic Viruses → Oncolytic Therapeutics
- Administration
- Intratumoral, Intravenous
01
Overview
TBIO-6517 + pembrolizumab is a combination investigational therapy for advanced solid tumors. TBIO-6517 is an oncolytic vaccinia virus, genetically attenuated to selectively infect and replicate in tumor cells. It is designed to stimulate local and systemic antitumor immune responses through direct oncolysis and immune activation. Pembrolizumab (Keytruda) is a monoclonal antibody checkpoint inhibitor that blocks the PD-1 receptor, lifting immune inhibition and promoting T-cell mediated cancer cell killing. This combination seeks to enhance antitumor immunity by pairing the immunogenic effects of intratumoral virotherapy (TBIO-6517) with systemic immune checkpoint blockade (pembrolizumab). Both direct intratumoral injection and intravenous modalities are tested.
- Other names
- TBIO-6517 + pembrolizumabTBio-6517 and pembrolizumabTBio6517 and pembrolizumabTBio 6517 and pembrolizumab
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)IL-12R (Interleukin-12 receptor)CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)FLT3 (Fms related receptor tyrosine kinase 3)
Beyond the preview
Go deeper on TBIO-6517 + pembrolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TBIO-6517 + pembrolizumab.